Immunotherapy for breast cancer is an active field of investigation, and the higher immunogenicity exhibited by the high expression FLI1 subtype compared to the low expression FLI1 subtype indicated that immunotherapy could be a viable option for the patients with the high FLI1 expression level. Here, FLI1 is linked to breast cancer.